CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced it has appointed two industry senior executives, Kurt Graves and David Maki, to its Board of Directors, effective immediately.
